| MCLOX | RLBGX | MCLOX / RLBGX | |
| Total Expense Ratio | 1.91 | 0.25 | 764% |
| Annual Report Gross Expense Ratio | 1.94 | 0.25 | 776% |
| Fund Existence | 31 years | 17 years | - |
| Gain YTD | 12.922 | 17.483 | 74% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 250 | 400% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 17.1B | 269B | 6% |
| Annual Yield % from dividends | 2.10 | 1.98 | 106% |
| Returns for 1 year | 6.06 | 10.16 | 60% |
| Returns for 3 years | 22.86 | 42.22 | 54% |
| Returns for 5 years | -5.96 | 40.93 | -15% |
| Returns for 10 years | 2.08 | 79.05 | 3% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBRN | 31.39 | 1.09 | +3.61% |
| iShares Neuroscience and Healthcare ETF | |||
| ETG | 22.50 | 0.11 | +0.49% |
| Eaton Vance Tax-Advantaged Global Dividend Income Fund | |||
| DDEC | 44.68 | 0.06 | +0.13% |
| FT Vest US Equity Dp Bfr ETF Dec | |||
| CEV | 10.40 | N/A | N/A |
| Eaton Vance California Municipal Income Trust | |||
| RND | 30.62 | N/A | N/A |
| First Trust Bloomberg R&D Leaders ETF | |||